Numerous studies have examined gene expression profiles in post-mortem human brain samples from individuals with schizophrenia compared with healthy controls, to gain insight into the molecular mechanisms of the disease. Although some findings have been replicated across studies, there is a general lack of consensus on which genes or pathways are affected. It has been unclear if these differences are due to the underlying cohorts or methodological considerations. Here, we present the most comprehensive analysis to date of expression patterns in the prefrontal cortex of schizophrenic, compared with unaffected controls. Using data from seven independent studies, we assembled a data set of 153 affected and 153 control individuals. Remarkably, we identified expression differences in the brains of schizophrenics that are validated by up to seven laboratories using independent cohorts. Our combined analysis revealed a signature of 39 probes that are upregulated in schizophrenia and 86 that are downregulated. Some of these genes were previously identified in studies that were not included in our analysis, while others are novel to our analysis. In particular, we observe gene expression changes associated with various aspects of neuronal communication and alterations of processes affected as a consequence of changes in synaptic functioning. A gene network analysis predicted previously unidentified functional relationships among the signature genes. Our results provide evidence for a common underlying expression signature in this heterogeneous disorder.
Introduction
Schizophrenia is a severe psychotic disorder that affects approximately 1% of the population worldwide. 1 Many groups have attempted to identify changes in gene expression in the brains of schizophrenics, often focusing on the prefrontal cortex. [2] [3] [4] Such studies have suggested several altered molecular processes including (but not limited to) synaptic machinery and mitochondrial-related transcripts, [5] [6] [7] [8] immune function 9 and a reduction in oligodendrocyte and myelination-related genes. [10] [11] [12] The variety and scope of these processes, found in different subject cohorts, raises the question as to whether there are underlying commonalities in molecular signatures among schizophrenics. Such commonalities are presupposed by most genetic studies, which look for alleles overrepresented in large numbers of schizophrenic individuals. [13] [14] [15] It is important to establish if there are any common features of the disease at the molecular level. The diversity of results in transcriptome studies can be attributed to many sources. Besides differences in the sampled cohorts and disease heterogeneity, discrepancies between transcriptome studies can be due to methodological differences in sample preparation, choice of platform and data analysis. There are issues that are especially pertinent to the analysis of post-mortem human brain tissue. One is the confounding effect of factors such as age, gender and medication. Such factors are often associated with relatively large gene expression changes, 16 while psychiatric illnesses such as schizophrenia are associated with small effect sizes. If these factors are not correctly controlled for, they can mask or masquerade as expression patterns associated with the disease. Standard practice involves minimizing the effects of such factors either in the experimental design by sample matching or treating these factors as covariates in regression models. It is also increasingly appreciated that technical artifacts such as 'batch effects' can result in substantial variability. [17] [18] [19] [20] In addition, post-mortem brain tissue is a limited resource, leading to small sample sizes with low statistical power. For this reason, most studies have not applied multiple test correction, and perform validation only on the same RNA samples that were used for profiling. All of these issues are likely to contribute to the differences in findings across studies. We propose that a good way to address these problems is to re-analyze and meta-analyze the studies in question, a task we undertake in this paper.
The use of meta-analyses to combine high-throughput genomics studies has become increasingly used in neuropsychiatry. 14, 17, [21] [22] [23] Combining data sets across studies increases power and facilitates the identification of gene expression changes that are consistent and reliable, reducing false positives. In a metaanalysis, multiple studies are statistically pooled to provide an overall estimate of significance of an effect, highlighting important yet subtle variations. Although meta-analysis has been used in the study of gene expression data, [24] [25] [26] to our knowledge only a few studies have done so with post-mortem human brain data. 17, 22, 27, 28 A cross-study analysis of psychosis was conducted across seven data sets using samples from the Stanley Medical Research Institute (SMRI) post-mortem brain collections. 22 Additionally, the SMRI report results from a cross-study analysis across schizophrenia data sets in their online genomics database (http://www.stanleygenomics.org), computing 'consensus' fold changes while adjusting for confounding variables. However, the studies used in these analyses use samples from the same two brain collections and are therefore not entirely independent. More recently, a comparative analysis was conducted across two independent schizophrenia cohorts; probes were identified as differentially expressed within each study and the intersecting probes between the two studies were reported. 29 Thus, while there have been attempts to meta-analyze schizophrenia expression profiling data, there has not yet been an integration using the primary data of more than two independent microarray studies.
In this study, we present a cross-study analysis of seven microarray data sets comprising a total of 153 schizophrenia samples and 153 normal controls. We applied a linear modelling approach to control for factors such as age, brain pH and batch effects, and applied multiple testing corrections to control the false discovery rate. We show that we are able to detect small yet consistent and statistically significant changes. Careful control of extraneous factors using probe-specific statistical modelling, results in gene expression changes associated with the disease effect. Our results confirm some previously reported expression changes in schizophrenia in addition to identifying potential new targets suggesting alterations in synaptic function.
Materials and methods
Data pre-processing and quality control Genome-wide expression data sets were selected on the basis of microarray platform, use of prefrontal cortex (BA 9, 10 or 46), the availability of information on covariates such as age, and finally the availability of the raw data. Each data set comprises a cohort of neuropathologically normal subjects and a cohort of schizophrenia subjects, as diagnosed and reported in their respective studies (Table 1) . Sources for data include the SMRI, the Harvard Brain Bank and the Gene Expression Omnibus (GEO). GEO studies were identified by extensive manual and keyword searches. Although the SMRI has additional data sets, these represent repeated runs of the samples from the same subjects, so we selected one data set to represent each of the two SMRI brain collections. Two additional studies were obtained from the investigators. 30, 31 Data sets consisted of single-channel intensity data generated from two Affymetrix (Santa Clara, CA, USA) platforms, but only probe sets on the HG-U133A chip from each data set were used for analysis. Probe sets were re-annotated at the sequence level by alignment to the hg19 genome assembly, using methods essentially as described in Barnes et al. 20 and also cross-referenced with problematic probe lists provided by http://masker.nci.nih.gov/ev/. The raw data ('CEL') files from all the data sets were pooled together and expression levels were summarized, log transformed and normalized by using the R Bioconductor 'affy' package (R Development Core Team, 2005) using default settings for the Robust Multi-array Average algorithm. Data were also processed using four other pre-processing methods for evaluating the robustness our meta-signatures (see Supplementary Text). We decided to retain standard Robust Multi-array Average as the method on which to center our analysis, because it has been shown independently to be a high performer on gold standard data sets. [32] [33] [34] Sample outliers were then identified and removed from each data set based on inter-sample correlation analysis (see Supplement), resulting in the removal of 13 samples (2 of these are the same outliers identified in a previous analysis of SMRI data; http://stanleygenomics.org). Batch information was obtained using the 'scan date' stored in the CEL files; chips run on different days were considered different batches. The final data matrix consisted of expression values for 22 215 probes sets and 306 samples. Sample characteristics for the subjects were collected and are summarized in Table 2 .
Statistical modelling
Gene expression values for each probe set were modeled using a standard fixed effects linear model framework. We treated disease, age, brain pH, batch date and study as fixed effects for which unknown constants are to be estimated from the data. We also employed a model selection procedure, in which each probe set was modeled using the full model including all five factors, as well as various sub-models (details in Supplementary Methods; our approach is similar to that used in Kent 35 ). For each probe set, the t-statistic for the disease effect was then extracted from the selected model and P-values were computed using one-sided tests, preformed independently for the two alternative null hypotheses (that is, gene expression does not increase with schizophrenia and gene expression does not decrease with schizophrenia). The resulting P-values for the up and downregulated signatures were further adjusted for multiple testing using the q-value method 36 to control the false discovery rate.
Literature-derived signatures
Our signatures were compared with probe lists obtained from the original publication for each of the data sets used in our analysis. As the two SMRI data sets were unpublished, gene lists were compiled from the SMRI online genomics database. For the Mclean data set, we used the list of 'significant probes' as reported in Maycox et al. 29 For the Haroutunian data, we chose to use probes selected at the 'low stringency criteria' described in Katsel et al. 31 Details on each of these gene sets can be found in Table 4 (probes were excluded if they were not on the HG-U133A chip). Additional signatures for comparison were obtained for published schizophrenia expression profiling studies, and a list of the top 45 candidate schizophrenia genes reported in the SZGene database. 13 Agreement of the metasignature ranking with each validation gene set was assessed using receiver operating characteristic curve analysis described in greater detail in Supplementary Methods.
Functional and network analysis
We analyzed each signature for enrichment of Gene Ontology terms, 37 using the gene score re-sampling method in ErmineJ. 38, 39 We also evaluated the pathlength and node degree (number of associations) properties of the meta-signature genes in a large human protein-protein interaction network obtained by aggregating data from multiple sources. [40] [41] [42] [43] [44] [45] The network contains 100 623 unique interactions among 11 697 genes. Path lengths in the network were measured using Dijkstra's algorithm. 46 Statistical significance was assessed by reference to an empirical null distribution obtained by randomly sampled 10 000 gene sets of similar size and node degree.
Results
Schizophrenia and control groups had no significant differences in age and post-mortem interval, and the number of males and females between the groups were fairly well matched (Table 2 ). Brain pH was significantly different (t-test; P = 0.001). P-value distributions for each demographic variable were also assessed to help determine the selection of factors used as fixed effects for our model. We found it was necessary to correct for 'batch effects' (technical artifacts caused by running chips on different days or even years 20 ), as they contributed the vast majority of variance in gene expression (Supplementary Figure 1) . Each factor was considered in a model selection procedure (see Materials and methods section and Supplementary Methods), and a final set of linear models were used to identify probe sets that were differential expressed between schizophrenic and control samples. After multiple test correction we identified a meta-signature of 39 upregulated and 86 downregulated probes at a false discovery rate of 0.1 (Supplementary Table 2, Table 3 ). If we assess the number of unique genes that appear in each signature, we obtain a list of 25 upregulated and 70 downregulated genes. These numbers highlight several cases of a gene which appears in our signature more There were 319 samples collected across seven data sets of which 306 passed quality control analysis. The summary demographics (mean ± s.d.) and t-test P-values for group differences are shown for those subjects used in the analysis. For sex, we report the P-value generated from a w 2 test for equality of proportions.
than once, suggesting higher confidence in the finding of expression changes for those genes. Figure 1 shows the expression levels top downregulated probe we identified. As expected, expression changes were small (B15% expression change) and more evident in some data sets. As required by our modelling procedure, the direction of expression changes is mostly consistent.
To test the robustness of these findings, we used a jackknife procedure, sequentially removing one of the seven studies and performing the meta-analysis on the remaining six, for each study in turn. We expected that results highly influenced by a single data set would not be stable across jackknife runs.
Each leave-out iteration resulted in a new metasignature, which was then ranked by q-value and compared against the final meta-signature (Supplementary Table 3 ). The range of rank correlations among jackknife iterations (0.87-0.99) illustrates the robustness of our meta-signatures, demonstrating that our results are not highly biased by any single data set. The lowest correlations were observed on removal of the Bahn and GSE21138 data sets (0.88 and 0.87, respectively) suggesting that these data sets may be contributing a slightly stronger signal, particularly to the upregulated signature. The lack of significant genes at a q < 0.1 in the signature for those jackknife runs corroborates this finding. Finally, the top 100 Altar study finding.
Expression profiling of schizophrenia using large cohort M Mistry et al probes were taken from each jackknife signature and an intersection set was retained to form a 'core signature' of 16 downregulated and 14 upregulated probes (Table 3) . We consider these probes to be the most reliable findings from our study as they are relatively insensitive to the choice of data sets used.
In Figure 2 , we have assembled the 'core signatures' and plotted expression levels within each data set with samples separated into control and schizophrenia groups. For some studies, we observe a more obvious gradient between the two groups illustrating expression change, and for others the difference is more subtle.
To assess the sensitivity of our results to the choice of pre-processing algorithm, we re-analyzed our data with four different methods (see Supplementary  Text) . We obtained good agreement between the results of each method and our final meta-signatures despite dramatic changes to the preprocessing procedure (Supplementary Table 4 ). Additionally, we took the intersection of significant probes from each of the different methods to assemble a list of probes that are completely insensitive to the choice of pre-processing method. This list comprises a total of five upregulated and eight downregulated probes, highlighting novel genes and genes that have been previously implicated in independent studies (Table 3; Supplementary  Table 2 ).
The set of differentially expressed genes identified from our analysis implicates a variety of genes and functional groups, many of which have been previously reported in the literature. For example, downregulation of mu-crystallin (CRYM), potassium channel subfamily K member 1 (KCNK1), F-box protein 9 (FBXO9) and upregulation of lipoprotein lipase (LPL) and lysyl hydroxylase 2 (PLOD2) are concordant with findings from previous studies. 7, 9, 12, 47 We manually evaluated the significant genes in our list (q < 0.1) individually according to literature reports and Uniprot definitions for each, to characterize genes into high-level functional categories. In the downregulated signature, we found genes to cluster into functional groups pertaining to various molecular mechanisms of neuronal communication. On the pre-synaptic side, we find genes involved in cell adhesion (for example, OPCML), and neurotransmitter secretion (for example, APBA2, PCSK2). We also find genes involved in signalling pathways that elicit metabotropic effects (for example, GNAL, OPN3, CRHR, RGS7, GNB5). Concordant with previous Figure 1 Example of consistent expression changes for a gene across data sets. Expression data within each data set after covariate correction is presented for the top downregulated gene NECAB3. Plots are labelled with the associated data set. Samples were separated into disease and control cohorts and expression was plotted as a boxplot. Individual sample values were overlaid on with squares representing control individuals and triangles representing schizophrenics.
Expression profiling of schizophrenia using large cohort M Mistry et al studies, we also identified various genes involved in oxidative phosphorylation (for example, CYP26B1, COQ4, SLC25A15, ATP5C1 and SLC25A12) and ubiquitination (for example, FBXO9, COPS7B, USP19, TACC2 and DCAF8). From our upregulated signature, we find a number of transcription-related genes (for example, BAZ1A, CBFA2T2, BBX and ANP32A) and genes involved in translation (for example, EIF3E, EIF2C3 and PAIP2B). Other genes include cell organization/maintenance factors (for example, PKP4 and PLOD2) and various stress response genes (for example, SMG1). Additionally, for both signatures we find a small group of genes with unknown function.
We performed a functional analysis to systematically detect enrichment of biological processes, using Gene Ontology annotations. After multiple test correction, we were unable to identify any significant terms using the over-representation method, but significant terms found using the threshold-free gene score re-sampling algorithm 39 corroborate findings from the above manual evaluation. For genes with decreasing expression levels in schizophrenia, the top Gene Ontology categories included those involved in energy metabolism, and ubiquitination, neurotransmitter transport and various metabolic processes. The schizophrenia upregulated genes showed enrichment in various immune-related Gene Ontology categories in addition to terms related to cellular localization (full results from this analysis can be found in Supplementary Table 5) .
As the genes we identified were functionally diverse, we hypothesized there might be additional insight gained at the level of gene networks. In particular, we asked whether the signature genes had any unusual properties in their protein interaction patterns, compared with carefully selected groups of background genes (see Materials and methods section). We specifically looked at within-group connectivity, node degree (the number of connections) and path lengths between genes. Our most striking finding is that the genes within our set were significantly closer to one another in the network than expected by chance (P < 0.02). This relationship suggests a higher likelihood of functional relationships among the signature genes. 41, 48 In contrast, the signature genes did not possess a particularly high node degree within the network (23rd percentile in the whole network), that is, they tend not to be 'hubs'. We illustrate these properties for the up and downregulated 'core' signature genes in Supplementary Figure 2 . Figure 2 Expression changes in the 'core signatures'. For each probe in the core signatures (meaning they are retained as significant even after the removal of any single study), the corresponding data from each study was extracted and converted to a heat map. Expression values were normalized across all samples within each data set, and as in Figure 1 We also evaluated each meta-signature against modules of co-expressed genes in the human cortex as reported in Oldham et al. 49 Details on this analysis can be found in the Supplementary Methods. Our up and downregulated signatures significantly overlap with the 'turquoise' and 'brown' modules (P < 0.01 and P < 0.05 respectively; Supplementary Table 6 ). These are modules of interest as they display a notable extent of preservation across data sets in Oldham et al., 49 suggesting that differential expression of our signature genes may be disrupting core networks in the human brain. This also reinforces the importance of gene network structure analysis in determining the basis of this disorder.
To characterize our schizophrenia signatures with respect to cellular organization in the cortex, we cross-referenced our ranked meta-signatures with published lists of central nervous system cell type markers. 50 A receiver operating characteristic analysis of the meta-signatures for astrocytes, oligodendrocytes and neurons revealed no preferential association with our ranked meta-signatures. However, evaluating only the significant probes (q < 0.1) in our signatures, we find an enrichment of probes mapping to neuronal markers in the downregulated signature (Supplementary Table 2 ). Although our linear modelling approach controlled for the effects of age and brain pH, we checked our signatures against gene lists for pH and age from our previous study of normal post-mortem human brain. 16 The overlap was significant only for our downregulated signature, which contains 33 genes previously identified to be downregulated by age. As our profiles are age-corrected and our cohorts age-matched, this suggests overlap in expression changes in age and schizophrenia rather than a confounding effect. We also sought to address factors that were not accounted for in our linear modelling, such as medication effects and alcohol and drug abuse. Using gene lists provided from the SMRI Online Genomics Database (http://www.stanleygenomics.org), we extracted significant gene lists (P < 0.001; fold change > 1.2) pertaining to the effects of lifetime alcohol use (23 genes), lifetime drug use (26 genes) and lifetime antipsychotics (69 genes) in subjects with schizophrenia. A comparison of each of these lists to our meta-signatures identified only two overlapping genes. We found KCNK1, which is present in our downregulated signature, also increases with lifetime alcohol use. From the upregulated signature the gene LPL, appears to increase with lifetime antipsychotic use and decrease with increased drug use.
Each meta-signature was evaluated against the top 45 candidate schizophrenia genes reported in the SZGene database (http://www.szgene.org/). Agreement of the meta-signature ranking with the SZGene set was assessed using receiver operating characteristic curve analysis. The SZGene list appears to be randomly distributed across our ranking. We also computed a simple overlap between the 45 candidate genes and our results, identifying OPCML as the only common gene.
We were interested in comparing our re-analysis of these seven data sets to the 'hit lists' provided by the data set providers. We first tested whether our meta-signature gene rankings were enriched for genes reported by the original study, using receiver operating characteristic analysis (Table 4 ; see Supplementary Methods). We observed high area under the curve scores for most gene sets; however, the Haroutunian and GSE21138 studies exhibited exceptionally low scores, possibly in part because the original studies have an added dimension of variability as gene sets were generated for stratified cohorts as opposed to a case vs control comparison. Although high area under the curves suggest some similarity in the results, a Abbreviations: AUC, area under the curve; ALR, average log ratio; DOI, duration of illness; FC, fold change; ROC, receiver operating characteristic. The findings from each data set are summarized including only probes used in our analysis. The 'Probes' column indicates number of probes found from the study based on study specific significance criteria. AUC values were computed from an ROC analysis of each gene set against the corresponding ranked meta-signatures. Overlap values report the number of probes in each gene set that overlaps with probes from the meta-signatures at q < 0.1.
more sensitive analysis examines just the very top of the rankings. We therefore computed the overlap of each reference gene set with the meta-signature of genes collected at q < 0.1. This reveals a handful of probes in each study that also show up in our significant gene lists (Table 4) . We also re-analyzed each individual data set using our linear modelling approach. This allowed a more fair evaluation of the contribution of each to the final meta-signatures, because the original studies used a variety of methods for gene selection. After correcting for multiple testing, only two of the data sets (Altar and Haroutunian) yielded significant genes at q < 0.1. We therefore considered the top 100 probes from each data set, and computed overlaps with our meta-signatures (Supplementary Table 7 ). The overlap is highest with the Bahn and GSE21138 data sets, which is in accord with the finding that these data sets contribute a stronger signal to the meta-signature than the others. Despite being the only two data sets, which have significant differential expression after multiple test correction, the Altar and Haroutunian results showed very little overlap with the final meta-signature. We note that considering the seven data sets independent of our meta-signature, there was no overlap among their top 100 probes. Similarly, there was little correlation of the overall rankings of probes among the data sets (Supplementary Table 8 ). Overall these results suggest that our re-analysis is concordant with the analysis conducted by the original study authors, subject to important differences likely attributable to our analytic approach (for example, correction for batch effects), and only revealing commonalities through meta-analysis, which contribute weakly to the findings of the individual studies.
Discussion
In this study, we present expression changes associated with schizophrenia consistent across up to seven independent cohorts of subjects. To our knowledge, the degree of validation and confirmation inherent in our analysis is unprecedented. Unlike previous studies, which use PCR assays to check results on the same RNA samples used for microarrays, or which compare at most two cohorts, we identified changes in expression that are shared across independent subject cohorts, analyzed by laboratories distributed around the world. Our study provides a new window into the molecular changes that might underlie schizophrenia. The larger number of downregulated probes (86 vs 39) is in agreement with previous reports. 2, 8, 9 Many of the genes we have identified have been previously reported to be expressed in the brain, with some genes showing neuronal specificity. Some of the genes we report as differentially expressed have been previously implicated in schizophrenia, either through expression profiling studies of schizophrenia (KCNK1, CRYM and FBXO9), or genetic association studies (OPCML). 15 We also identify three genes in our signature (upregulated genes WNK1 and ABCA1 and downregulated gene SNN) that overlap with results from a comparative analysis of two of the studies we used. 29 Additionally, we found functional gene groups discussed in previous expression studies of schizophrenia. Many of the same metabolic processes were observed in a study of 71 different metabolic genes groups in schizophrenia. 7 Also in agreement, various energy pathway genes were found previously in DLPFC studies of schizophrenia. 47, 51 Overexpression of immune responses from our gene score re-sampling analysis is also concordant with recent findings of overexpression in genes related to immune function in schizophrenia. 9, 52, 53 Thus, our results are supportive of at least some previous findings and reveal a previously unrecognized similarity across studies.
Our meta-signatures contain a number of interesting new candidate genes, particularly our downregulated meta-signature, which potentially reflects alterations in neuronal communication. NOVA1 is a regulator of RNA splicing recently found to inhibit splicing of exon6 from the dopamine receptor D2 gene resulting in D2L, the long isoform of the receptor. 54 With NOVA1 decreasing in expression in schizophrenia, inhibition may be repressed leading to higher than normal levels of the spliced D2S isoform, which is involved in neuron firing and dopamine release. The DLGAP1 gene encodes a protein interacting with PSD-95 and a complex of other proteins in the postsynaptic density. Decreased expression of this scaffold protein may have consequences for anchoring and organizing receptors and signalling molecules on the postsynaptic side. Moreover, we have identified several genes associated with calcium signalling (CACNB3), binding (SLC25A12, NECAB3) and homeostasis (CCL3, ATP2B2), processes of likely relevance to schizophrenia. 55 We have also identified genes that associate with the G-protein coupled receptor signalling pathway. One example is GNAL, a gene encoding for the alpha subunit of the G-protein Golf, expressed in many regions of the brain. Given the critical roles of G-proteins it is plausible that GNAL (and other G-protein coupled receptor-related genes) may have a role in the pathophysiology of schizophrenia. 56 GNAL expression has not been previously shown to be affected by schizophrenia, but it is located in a chromosomal region (18p.2) that has been linked to schizophrenia and bipolar disorder. More specifically, a di-nucleotide repeat in intron 5 of the GNAL gene has been linked to schizophrenia in some families. 57 These expression changes concerning synaptic function may reduce neuronal energy demand in the brains of affected patients thus providing explanation for the downregulation of various oxidative phosphorylation and energy metabolism genes that we observe.
We also sought to examine whether our signature genes could be inferred to share some previously unknown function, making use of gene network analysis. One way to do this is by the principle of Expression profiling of schizophrenia using large cohort M Mistry et al 'guilt by association', which states that genes with shared function are more likely to interact. 58 However, the meta-signature genes have a fairly low number of interaction partners, making 'guilt' difficult to ascertain. Another property to examine is path length in the network, where genes that have short paths between them might be more functionally related. In general, low node degrees would imply higher path lengths among the genes, but was not the case for our gene set. That is, the signature genes are linked by unusually short paths in the network. Additionally, we found each of our meta-signatures revealed a significant overlap with previously identified gene co-expression modules in the human cortex. 49 This suggests a relationship among the genes that is not reflected in current annotations and a network analysis of these schizophrenia genes will need to be investigated in greater detail in future studies.
We found that some of the downregulated schizophrenia genes overlap with genes that decrease in expression with age. Many of the biological processes affected by age also tend to appear as affected processes in schizophrenia, both in this study and existing profiling studies. 7, 9, 12, 47, 51 These findings suggest that many genes affected by age are also affected by schizophrenia, but also raise the possibility of confounding effects. As these effects could be confounded, one could filter the list of schizophrenia candidate genes from our results by simply removing known age-and pH-affected genes from the final signature (leaving 31 up and 51 downregulated probes) to investigate these effects more thoroughly.
Our results should be interpreted in the context of several caveats. First, our approach is specifically designed to find concordant results across studies, and does not detract from the potential novel findings that might be found in any single data set. We do suggest that genes found to be commonly differentially expressed by multiple studies are of particularly high value in identifying underlying etiological influences in schizophrenia. As is the case for all postmortem brain studies, we also cannot be sure that the expression changes we have identified are direct effects of the illness or are secondary to an underlying pathology. An additional caveat is that because we were unable to obtain medication or illicit drug use information for all subjects, we were not able to incorporate this information into our analysis. To help address this, we compared our signatures against gene lists derived from a recent review on convergent antipsychotic mechanisms. 59 We observed no overlap with our signatures. In addition to anti-psychotics, the use and abuse of other recreational drugs and smoking are also compounds that can confound the study of disease-related gene expression. Owing to a lack of sufficient information on these factors, we were unable to strictly control for them in our analysis. However, using gene lists provided from the SMRI Online Genomics Database (http://www. stanleygenomics.org) we were able to make comparisons with address some of these factors and identified two overlapping genes. Although the small number of overlapping genes is suggestive that we have identified genes in our signature that are not affected by such extraneous factors; we acknowledge that we cannot entirely exclude the possibility that the gene expression changes we have identified are still in some way influenced.
In conclusion, we have contributed the most comprehensive meta-analysis of schizophrenia expression profiling studies to date. Our most striking finding is that despite the heterogeneity of the disorder, we were able to detect a common signature of schizophrenia. Additionally, we have elaborated on the biological relevance of our gene list, illustrating a need for further genetic study to fully enhance our understanding of the direct implication of these changes in expression with the illness. The signatures we identified are consistent with current hypotheses of molecular dysfunction in schizophrenia, including alterations in synaptic transmission and energy metabolism. However, the diversity of genes we found suggests that systems biology approaches, exemplified by the analysis of gene network structure, will be of value in determining the basis of this disorder. The approaches used in our study should be applicable to other neuropsychiatric disorders if sufficient data are available.
